If RAP locks in commercial deals in Australia or Europe I see no problem in the market valuing it as $1 per share even on the first few deals. The market is forward looking and P/E ratios are high in this industry. The most important thing about RAP is how 'scalable' it is and low cost/overheads. Can literally be distributed and implemented worldwide with ease.
Ann: TGA Approval for Paediatric Respiratory Disease Diagnosis, page-19
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)